• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stronger Q2 Results And Higher 2026 Guidance Might Change The Case For Investing In Omnicell (OMCL)

    Simply Wall St·07/30/2026 19:21:40
    Listen to the news
    • Omnicell, Inc. has reported past second-quarter 2026 results showing revenue of US$312.21 million and net income of US$24.29 million, alongside stronger earnings per share and improved performance for the first half of the year compared with the prior period.
    • The company also issued revenue guidance of US$301 million–US$307 million for the third quarter and US$1.23 billion–US$1.25 billion for full-year 2026, giving investors clearer visibility into its near-term growth trajectory.
    • With Omnicell’s updated full-year 2026 revenue guidance now set above US$1.22 billion, we’ll examine how this reshapes its investment narrative.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    Omnicell Investment Narrative Recap

    To own Omnicell, you need to believe that hospitals and health systems will keep investing in medication automation and that Omnicell can turn that demand into improving profitability. The latest second quarter beat and higher full year 2026 revenue guidance help the near term earnings story, but they do not remove key risks around tariff costs and potential pressure on hospital capital budgets.

    The most relevant recent announcement is the updated 2026 revenue outlook of US$1.225 billion to US$1.245 billion, coming alongside stronger first half earnings. This tighter, slightly higher range gives you more concrete near term benchmarks against which to judge whether Omnicell is making progress on its shift toward more recurring revenue and better margins, or whether competitive and macro pressures are still the more important forces.

    Yet beneath the improved guidance, investors should still be aware of the risk that hospital budget constraints could...

    Read the full narrative on Omnicell (it's free!)

    Omnicell's narrative projects $1.4 billion revenue and $71.2 million earnings by 2029. This requires 4.4% yearly revenue growth and about a $50.8 million earnings increase from $20.4 million today.

    Uncover how Omnicell's forecasts yield a $61.29 fair value, a 48% upside to its current price.

    Exploring Other Perspectives

    OMCL 1-Year Stock Price Chart
    OMCL 1-Year Stock Price Chart

    Before this earnings beat, the most optimistic analysts were already assuming Omnicell could reach about US$1.4 billion of revenue and US$83 million of earnings by 2029, which is a much more upbeat view than caution around slower OmniSphere adoption suggests, and this new information may push some of those expectations in either direction as you compare these very different stories.

    Explore 4 other fair value estimates on Omnicell - why the stock might be worth just $60.12!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Omnicell research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Omnicell research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Omnicell's overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.